Saltar al contenido
Merck

QKI5-mediated alternative splicing of the histone variant macroH2A1 regulates gastric carcinogenesis.

Oncotarget (2016-04-20)
Feng Li, Ping Yi, Jingnan Pi, Lanfang Li, Jingyi Hui, Fang Wang, Aihua Liang, Jia Yu
RESUMEN

Alternative pre-mRNA splicing is a key mechanism for increasing proteomic diversity and modulating gene expression. Emerging evidence indicated that the splicing program is frequently dysregulated during tumorigenesis. Cancer cells produce protein isoforms that can promote growth and survival. The RNA-binding protein QKI5 is a critical regulator of alternative splicing in expanding lists of primary human tumors and tumor cell lines. However, its biological role and regulatory mechanism are poorly defined in gastric cancer (GC) development and progression. In this study, we demonstrated that the downregulation of QKI5 was associated with pTNM stage and pM state of GC patients. Re-introduction of QKI5 could inhibit GC cell proliferation, migration, and invasion in vitro and in vivo, which might be due to the altered splicing pattern of macroH2A1 pre-mRNA, leading to the accumulation of macroH2A1.1 isoform. Furthermore, QKI5 could inhibit cyclin L1 expression via promoting macroH2A1.1 production. Thus, this study identified a novel regulatory axis involved in gastric tumorigenesis and provided a new strategy for GC therapy.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-QKI-5 Antibody, serum, Chemicon®